Aclaris Therapeutics is in the biotechnology industry and healthcare sector. The company CEO is Neal Walker. Aclaris Therapeutics Inc is a clinical-stage specialty pharmaceutical company which focuses on identifying, developing and commercializing differentiated drugs to address significant unmet needs in dermatology.
Previous Intraday Performance:
The ACRS shares had a previous change of 1.79% which opened at 5.08 and closed at 5.12. It moved to an intraday high of 5.13 and a low of 4.85.
SeekingAlpha: Daily Insider Ratings Round Up 5/13/19
Historical Performance:
Over the last five trading days, ACRS shares returned -3.03% and in the past 30 trading days it returned -15.09%. Over three months, it changed -21.71%. In one year it has changed -73.18% and within that year its 52 week high was 21.97 and its 52 week low was 4.73. ACRS stock is 8.24% above its 52 week low.
Our calculations result in a 200 day moving average of 9.42 and a 50 day moving average of 6.07. Right now, ACRS stock is trading -45.62% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.
SeekingAlpha: Daily Insider Ratings Round Up 5/13/19
Liquidity:
The company has a market cap of $211.3m with 41.3m shares outstanding and a float of 39.5m shares. Trading volume was 745,073 shares and has experienced an average volume of 618,011 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
Earnings:
The last annual reported EPS for Aclaris Therapeutics was -4.04 which ended on 31st of December 2018. Based on 2 analyst estimates, the consensus EPS for the next quarter is -0.77.
Below was the last reported quarterly diluted earnings per share:
| 1st | Qtr 2019 | -0.91 |
|---|---|---|
| 4th | Qtr 2018 | -0.99 |
| 3rd | Qtr 2018 | -1.06 |
| 2nd | Qtr 2018 | -1.01 |
| 1st | Qtr 2018 | -0.98 |
The growth of the EPS is critical in understanding the current valuation of Aclaris Therapeutics; it is usually expressed as a percentage and is then referred to as the EPS growth rate, which at this time is hard to estimate, but revenue growth has been 322.80% over the last twelve months.
Indicators Also to Watch:
The beta was calculated to be 1.36.
SeekingAlpha: Axcelis Technologies, Inc. (ACLS) CEO Mary Puma on Q1 2019 Results – Earnings Call Transcript
Fundamental Numbers:
Based on last reported financials, the company’s return on equity is -73.20%, return on assets is -59.13%, price-to-sales is 16.59 and price-to-book is 1.16.
Company Score Card:
Results are out of six:
5 : Growth Expectations Result
5 : Financial Safety Result
0 : Past Performance Result
1 : Valuation Result
0 : Dividend Safety Result
2 : Overall Result
Related Tags: Aclaris Therapeutics, ACRS, Biotechnology, Healthcare
